GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lineage Cell Therapeutics Inc (XTAE:LCTX) » Definitions » Repurchase of Stock

Lineage Cell Therapeutics (XTAE:LCTX) Repurchase of Stock : ₪-0.08 Mil (TTM As of Sep. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Lineage Cell Therapeutics Repurchase of Stock?

Lineage Cell Therapeutics's Repurchase of Stock for the three months ended in Sep. 2024 was ₪0.00 Mil.

Lineage Cell Therapeutics's Repurchase of Stock for the trailing twelve months (TTM) ended in Sep. 2024 was ₪-0.08 Mil.


Lineage Cell Therapeutics Repurchase of Stock Historical Data

The historical data trend for Lineage Cell Therapeutics's Repurchase of Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lineage Cell Therapeutics Repurchase of Stock Chart

Lineage Cell Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Repurchase of Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.39 -0.10 -0.19 -0.06 -0.13

Lineage Cell Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Repurchase of Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - -0.08 - -

Lineage Cell Therapeutics Repurchase of Stock Calculation

A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of Stock represents the cash outflow to reacquire common stock during the period.

Repurchase of Stock for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₪-0.08 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Lineage Cell Therapeutics Repurchase of Stock Related Terms

Thank you for viewing the detailed overview of Lineage Cell Therapeutics's Repurchase of Stock provided by GuruFocus.com. Please click on the following links to see related term pages.


Lineage Cell Therapeutics Business Description

Traded in Other Exchanges
Address
2173 Salk Avenue, Suite 200, Carlsbad, CA, USA, 92008
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.